EN | RU
EN | RU

Help Support

Back

Study evaluates patient-reported improvements in psoriatic arthritis following ixekizumab treatment

Study evaluates patient-reported improvements in psoriatic arthritis following ixekizumab treatment Study evaluates patient-reported improvements in psoriatic arthritis following ixekizumab treatment
Study evaluates patient-reported improvements in psoriatic arthritis following ixekizumab treatment Study evaluates patient-reported improvements in psoriatic arthritis following ixekizumab treatment

The study was conducted to investigate the onset and sustainability of patient-reported improvements in symptoms of PsA subjects after treatment with IXE up to Week 108.

See All

Key take away

PsA (Psoriatic arthritis) causes painful joint inflammation. In patients with PsA, the study assessing patient-reported improvements in signs and symptoms with IXE (ixekizumab) treatment illustrated that IXE-treated patients achieved substantially greater improvements and faster onset of improvements in patient-reported outcomes in comparison with placebo. The responses were generally consistent regardless of prior TNFi (tumor necrosis factor inhibitor) experience and were sustained over 2 years.

Background

The study was conducted to investigate the onset and sustainability of patient-reported improvements in symptoms of PsA subjects after treatment with IXE up to Week 108.

Method

Patients with active PsA were randomized to either naive to biological DMARDs (Disease-modifying anti-rheumatic drugs) (SPIRIT-P1) or having inadequate response or intolerance to 1 or 2 prior TNF-i (TNFi-experienced; SPIRIT-P2). A change from baseline in joint pain VAS (visual analogue scale; 0-100 scale), patient global assessment VAS (0-100 scale), fatigue NRS (numerical rating scale, 0 to 10), and HAQ-DI (Health Assessment Questionnaire-Disability Index, 0-3) was examined up to Week 108.

Result

In patients treated with IXE, rapid and statistically significant improvement was witnessed in joint pain VAS, HAQ-DI, and patient global assessment as early as Week 1 when compared to the placebo group. This benefit was found to be sustained or increased through Week 108. In IXE-treated patients, the fatigue scores improved in comparison to placebo. At Week 24, the results were statistically significant only in SPIRIT-P2. Improvements in fatigue with IXE were sustained over 2 years. The improvements witnessed in these patient-reported outcomes were consistent in biologic-naive or TNFi-experienced individuals.

Conclusion

In biologic-naive and TNF-inadequate responder patients with PsA, treatment with IXE causes rapid and sustained improvements in patient-reported signs and symptoms up to Week 108.

Source:

Clinical and Experimental Rheumatology

Article:

Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms With Ixekizumab in Biologic-Naive and TNF-inadequate Responder Patients With Psoriatic Arthritis

Authors:

Ana-Maria Orbai et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: